Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019

Share

News 13/12/2019

**Five new medicines recommended for approval**

EMA’s human medicines committee ([CHMP](https://www.ema.europa.eu/en/glossary/chmp)) recommended five medicines for approval at its December 2019 meeting.

The Committee recommended granting a [marketing authorisation](https://www.ema.europa.eu/en/glossary/marketing-authorisation) for **Beovu** (brolucizumab) for the treatment of neovascular (‘wet’) age-related macular degeneration, a disease that affects the central part of the retina at the back of the eye and causes loss of ‘straight-ahead’ vision.

The [CHMP](https://www.ema.europa.eu/en/glossary/chmp) adopted a positive opinion for **Recarbrio** (imipenem / cilastatin / relebactam), for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

The [biosimilar medicine](https://www.ema.europa.eu/en/glossary/biosimilar-medicine) **Amsparity** (adalimumab) received a positive opinion for the treatment of certain inflammatory and autoimmune disorders.

The [CHMP](https://www.ema.europa.eu/en/glossary/chmp) recommended granting [marketing authorisations](https://www.ema.europa.eu/en/glossary/marketing-authorisation) for two [generic medicines](https://www.ema.europa.eu/en/glossary/generic-medicine): **Azacitidine Accord**(azacitidine), for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia, diseases in which the body produces large numbers of abnormal blood cells; and **Dexmedetomidine Accord** (dexmedetomidine), for the induction of light to moderate sedation of adults in an intensive care unit.

**Eight recommendations on extensions of therapeutic indication**

The Committee recommended extensions of [indication](https://www.ema.europa.eu/en/glossary/indication) for **Akynzeo**, **Cyramza**, **Darzalex**, **Dificlir**, **Erleada**, **Sirturo**,**Stelara**and**Vyndaqel**.

**Agenda and minutes**

The agenda of the December meeting is published on EMA's website. Minutes of the November 2019 [CHMP](https://www.ema.europa.eu/en/glossary/chmp" \t "_blank" \o "Committee for Medicinal Products for Human Use -  the committee that is responsible for preparing the Agency's opinions on questions concerning human medicines.   More information can be found under 'Committee for Medicinal Products for Human Use (CHMP)'.)meeting will be published in the coming weeks.

**CHMP statistics**

Key figures from the December 2019 [CHMP](https://www.ema.europa.eu/en/glossary/chmp) meeting are represented in the graphic below.